Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 18/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 16/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24615076 | 0.73 | ADORA2A (0.54) | ADORA3ADORA2AADORA1 | |
| SCHEMBL4387417 | 0.71 | ADORA3 (1.00) | ADORA3ADORA2AADORA1 | |
| SCHEMBL31061129 | 0.71 | ADORA3 (1.00) | ADORA3ADORA2AADORA1 | |
| SCHEMBL27430176 | 0.71 | CDK1 (0.63) | ADORA3ADORA2AADORA1 | |
| SCHEMBL6384536 | 0.70 | ADORA3 (0.57) | ADORA3ADORA2AADORA1 | |
| SCHEMBL24615077 | 0.70 | ADORA3 (0.54) | ADORA3ADORA2AADORA1 | |
| SCHEMBL24707891 | 0.70 | ADORA3 (0.62) | ADORA3ADORA2AADORA1 | |
| SCHEMBL25566237 | 0.70 | ADORA3 (0.72) | ADORA3ADORA2AADORA1 | |
| SCHEMBL24178186 | 0.70 | ADORA3 (0.62) | ADORA3ADORA2AADORA1 | |
| SCHEMBL25612785 | 0.70 | ADORA3 (0.62) | ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-06-01 | — | — | US | disclosed |
| US-11484545-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220000899-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11484545-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA2A 436/4885ADORA1 994/4885 |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA2A 436/4885ADORA1 994/4885 |
| US-20220000899-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA2A 436/4885ADORA1 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.